Scilex Holding (SCLXW) Cash from Financing Activities (2020 - 2026)

Scilex Holding (SCLXW) recorded quarterly Cash from Financing Activities of $9.1 million in Q1 2026, down 47.81% quarter-over-quarter from $17.5 million in Q4 2025, and up 396.5% on a YoY basis from $1.8 million in Q1 2025.

Scilex Holding (SCLXW) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Scilex Holding's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 396.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 167.54% YoY), while the FY2025 annual figure was -$5.5 million, up 69.88% from the prior year.
  • Cash from Financing Activities was $9.1 million for Q1 2026 at Scilex Holding, down from $17.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $43.5 million in Q2 2023 to a low of -$38.9 million in Q3 2023.
  • Historically, Cash from Financing Activities has averaged $1.8 million across 5 years, with a median of -$3.1 million in 2025.
  • Biggest YoY gain for Cash from Financing Activities was 1849.77% in 2023; the steepest drop was 466.26% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $426000.0 in 2022, then jumped by 1849.77% to $8.3 million in 2023, then plunged by 186.48% to -$7.2 million in 2024, then soared by 343.91% to $17.5 million in 2025, then tumbled by 47.81% to $9.1 million in 2026.
  • The last three Cash from Financing Activities figures came in at $9.1 million (Q1 2026), $17.5 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 366.70 Mn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -3.47 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 530.00 Mn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 919.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -2.98 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.44 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -4.24 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -2.86 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -1.56 Bn
10 Scilex Holding - - 4.15 Mn 9.14 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 9.14 Mn
Mar 31, 2026 9.14 Mn
Dec 31, 2025 17.52 Mn
Dec 31, 2025 17.52 Mn
Sep 30, 2025 -11.30 Mn
Sep 30, 2025 -11.30 Mn
Jun 30, 2025 -8.60 Mn
Jun 30, 2025 -8.60 Mn
Mar 31, 2025 -3.08 Mn
Mar 31, 2025 -3.08 Mn
Dec 31, 2024 -7.18 Mn
Dec 31, 2024 -7.18 Mn
Sep 30, 2024 -4.48 Mn
Sep 30, 2024 -4.48 Mn
Jun 30, 2024 4.73 Mn
Jun 30, 2024 4.73 Mn
Mar 31, 2024 -11.20 Mn
Mar 31, 2024 -11.20 Mn
Dec 31, 2023 8.31 Mn
Dec 31, 2023 8.31 Mn